Workshop #1: Psychedelics: Promising Treatment Applications and Concerns for Impaired Driving

Date: Monday October 28, 2024
Time: 8:00 AM – 12:00 PM

Rate:

<table>
<thead>
<tr>
<th></th>
<th>MEMBER RATES</th>
<th>NON – MEMBER RATES</th>
</tr>
</thead>
</table>
| Early Bird Registration | June 26 – September 11               | On-site Registration
|                          | $150                                 | Begins October 10
| Late Registration       | Begins September 12                  | $200                                |
|                        | $175                                 | On-site Registration
|                        |                                       | Begins October 10
|                        |                                       | $250                                |

Chairs
Kristin W. Kahl, M.S., D-ABFT-FT, NRCC-TT
Toxicologist 3/Supervisor
University of Miami Toxicology Laboratory
kwkahl@miami.edu

Michael A. Wagner, Ph.D., F-ABFT
Faculty
Indiana University School of Medicine, Purdue University School of Science
micawagn@iupui.edu

Abstract
The SOFT/AAFS Drugs and Driving Committee presents a workshop examining the use of psychedelic drugs to treat psychiatric disorders and the impact these drugs have on driving under the influence of drugs (DUID) casework. States are now using the “right-to-try” 1 to expand the use of entheogenic plants including psilocybin mushrooms, ibogaine, dimethyltryptamine (also known as “DMT”), ayahuasca, peyote (mescaline), and hallucinogens like MDMA and LSD. Psychedelic drugs listed above and the dissociative anesthetic ketamine (including esketamine (Spravato)), are being investigated or currently used in the treatment of mental health illnesses such as, major depressive disorders, post-traumatic stress (PTSD), obsessive compulsive disorder (OCD), and possibly substance use disorder (SUD). The increase over the past decade in research and private clinical use of these psychedelic/hallucinogenic drugs has the potential to result in an increase prevalence of recreational use and detection in DUID cases.

This workshop will discuss the history of and current use of psychedelics to treat psychiatric disorders and their pharmacological properties that contribute to their clinical effectiveness. The workshop will focus on the following drugs: Psilocybin, LSD, MDMA, and Ketamine/Esketamine. The detection and significance of these drugs in DUID casework will also be discussed. The attendees will be provided with current DUID trends and DUID examples that include psychedelic drugs.

1. Psychedelics Drug Legislative Reform and Legalization in the US; JAMA Psychiatry. 2023 January 01; 80(1): 77–83; Siegel, J.S. et.al.
Learning Objectives

1. Inform attendees of the use of psychedelic drugs to treat mental illnesses and disorders.
2. Discuss the pharmacology of hallucinogenic and dissociate anesthetic drugs as it applies to clinical treatment and impairment of human performance.
3. Provide current DUID trends and case examples of DUID cases involving psychedelics.

Faculty
Michael A. Wagner, Ph.D., F-ABFT
Faculty
Indiana University School of Medicine, Purdue University School of Science
micawagn@iupui.edu

Kristin W. Kahl, M.S., D-ABFT-FT, NRCC-TT
Toxicologist 3/Supervisor
University of Miami Toxicology Laboratory
kwkahl@miami.edu

Alexander Thomas, M.D.
Addiction Psychiatry Fellow
Indiana University School of Medicine, Department of Psychiatry
thomaals@iupui.edu

Joshua S. Siegel, M.D., Ph.D.
Director, Translational Medicine
Sumitomo Pharma America
joshsiegelmdphd@gmail.com

Audience Knowledge Level:
Basic

Workshop Agenda

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00-8:10 am</td>
<td>Welcome/Introductions</td>
<td>Kristin Kahl/Michael A. Wagner</td>
</tr>
<tr>
<td>8:10-9:10 am</td>
<td>MDMA, Psilocybin, and LSD: clinical perspective and neuropsychopharmacology</td>
<td>Joshua Siegel</td>
</tr>
<tr>
<td>9:10-10:00 am</td>
<td>Ketamine for the Treatment of Substance Use Disorder</td>
<td>Alexander Thomas</td>
</tr>
<tr>
<td>10:00-10:30 am</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>10:30-11:10 am</td>
<td>MDMA and Psilocybin: DUID case interpretations and trends</td>
<td>Kristin Kahl</td>
</tr>
<tr>
<td>11:10-11:50 am</td>
<td>LSD and Ketamine a forensic toxicology perspective including DUID cases</td>
<td>Michael A. Wagner</td>
</tr>
<tr>
<td>11:50-12:00 pm</td>
<td>Q&amp;A Panel</td>
<td>All Speakers</td>
</tr>
</tbody>
</table>